Idorsia Ltd.
0RQE.IL
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.03B
Close$
Share Statistics
| Market cap | $2.03 Billion |
|---|---|
| Enterprise Value | $3.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | 2.47 |
| Outstanding Shares | - |
Return
| Return on Equity | 26.53% |
|---|---|
| Return on Assets | -68.28% |
| Return on Invested Capital | -249.69% |
Valuation & Multiples
| P/E Ratio | -3.2 |
|---|---|
| PEG | -0.38 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 16.35 |
| Enterprise Value to EBIT | -16.51 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | -1.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$49.50 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$53.75 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Idorsia Ltd.
487 employees
CEO: Jean-Paul Clozel Idorsia Ltd. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of medicines for medical needs. It operates through the following geographical segments: Switzerland, United States, Japan, a...